National Skin Centre, Singapore.
Department of Occupational and Environmental Medicine, Singapore General Hospital, Singapore.
Indian J Dermatol Venereol Leprol. 2020 Mar-Apr;86(2):162-168. doi: 10.4103/ijdvl.IJDVL_751_17.
Ultraviolet-A1 phototherapy has been used to treat many inflammatory dermatoses.
To determine the efficacy and safety of ultraviolet-A1 phototherapy in Asian skin.
We performed a review of records of patients undergoing ultraviolet-A1 phototherapy at our dermatology unit in Singapore from January 2007 to January 2011. Their electronic medical records were reviewed and a standardized questionnaire was filled up for data collection and tabulation. Chi-square or Fisher's exact tests were used to compare the difference in response between various groups for each characteristic. P value of < 0.05 was considered statistically significant.
Our study comprised of 159 patients, of which 103 were patients with hand and foot eczema, 21 with atopic dermatitis, 17 with scleroderma and the remaining with miscellaneous dermatoses. Of these patients, 47.6% of patients with hand and feet eczema had good response after 10 sessions, which increased to 75% after 20 sessions and to 84.6% after 30 sessions. After 10 sessions, 47.6% of patients with atopic dermatitis had good response, which increased to 66.7% after 20 sessions. After 30 sessions, all the three remaining patients with atopic dermatitis experienced good response. For patients with scleroderma, only 11.8 and 10% had good response after 10 and 20 sessions, respectively, which increased to 40% after 30 sessions.
Limitations of our study include its retrospective design and, consequently, the lack of standardized treatment protocol, as well as subjective assessment in terms of clinical improvement.
Ultraviolet-A1 phototherapy appears to be efficacious for the treatment of hand and foot eczema as well as atopic dermatitis. However, in patients with scleroderma, the response was partial and needed a longer duration of treatment.
紫外线 A1 光疗已被用于治疗许多炎症性皮肤病。
确定紫外线 A1 光疗在亚洲皮肤中的疗效和安全性。
我们对 2007 年 1 月至 2011 年 1 月在新加坡皮肤科单位接受紫外线 A1 光疗的患者记录进行了回顾。对他们的电子病历进行了审查，并填写了标准化问卷以进行数据收集和制表。对于每个特征，使用卡方检验或 Fisher 确切检验比较不同组之间的反应差异。P 值 < 0.05 被认为具有统计学意义。
我们的研究包括 159 名患者，其中 103 名患者患有手和足湿疹，21 名患者患有特应性皮炎，17 名患者患有硬皮病，其余患者患有各种皮肤病。在这些患者中，47.6%的手和足湿疹患者在 10 次治疗后有良好的反应，在 20 次治疗后增加到 75%，在 30 次治疗后增加到 84.6%。在 10 次治疗后，47.6%的特应性皮炎患者有良好的反应，在 20 次治疗后增加到 66.7%。在 30 次治疗后，其余 3 名特应性皮炎患者均有良好的反应。对于硬皮病患者，仅 11.8%和 10%在 10 次和 20 次治疗后有良好的反应，在 30 次治疗后增加到 40%。
我们研究的局限性包括其回顾性设计，因此缺乏标准化的治疗方案，以及临床改善方面的主观评估。
紫外线 A1 光疗似乎对治疗手和足湿疹以及特应性皮炎有效。然而，在硬皮病患者中，反应是部分的，需要更长的治疗时间。
